This is a company's preclinical claim, not an established treatment. Dr. Thomas Ichim, president and chief scientific officer of Immorta Bio, posted the announcement on X. The candidate is SenoMune-0257, a synthetic peptide of nine amino acids that the company says was designed with AI. It is meant to stimulate cytotoxic T cells to clear senescent cells, the aging cells that stop dividing but linger in tissue.
Immorta's press release of October 12, 2026 says preclinical studies are complete. Its lab results showed selective killing of senescent cells while sparing healthy cells 'under the conditions tested.' Coverage this week, such as BusinessToday, says human testing could start before the end of 2026. No trial start is confirmed, and human safety and efficacy have not been established.
On the wording: the post calls it a cancer immunotherapy that fights aging. The company's case is that it targets senescent cells, which it links to many age-related diseases, and that its earlier SenoVax work showed tumor suppression in experimental models. Animal and cell results don't yet show how it would work in people, and 'first' is a claim the field hasn't checked. The useful next steps are a trial registration or a peer-reviewed paper.
Also discussed here:
- The First Blood Test for Fifty Cancers Reached the FDA Today. It St…
- Pancreatic Cancer Has a Drug That Works. Now the FDA Wants It Tried…
🕒 As of October 2026
